Estrella Immunopharma Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
| For the Nine Months · For the Nine Months | ||||
|---|---|---|---|---|
| Ended · Ended | ||||
| March 31, 2024 · March 31, 2023 | ||||
| Cash Flows from Operating Activities: | ||||
| Net loss | $(3,360,651) | $(8,382,890) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 1,194,653 | 307,197 | ||
| Amortization of operating right-of-use asset, related party | - | 14,473 | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses | (267,343) | (50,000) | ||
| Prepaid expenses - related party | (3,500,000) | 833,333 | ||
| Accounts payable - related party | (9,333,146) | 5,925,271 | ||
| Other payables and accrued liabilities | (492,368) | 55,813 | ||
| Operating lease liability - related party | - | 1,527 | ||
| Accrued liability - related party | (18,000) | - | ||
| Franchise tax payable | 62 | 2,400 | ||
| Net cash used in operating activities | (15,776,793) | (1,292,876) | ||
| Cash Flows from Investing Activities: | ||||
| Loan to UPTD as extension note receivable prior to business combination | (112,298) | (136,533) | ||
| Cash released from trust account | 5,072,945 | - | ||
| Net cash provided by investing activities | 4,960,647 | (136,533) | ||
| Cash Flows from Financing Activities: | ||||
| Payments of transactions cost | (1,525,013) | - | ||
| Net proceeds from PIPE investment | 10,000,000 | - | ||
| Net proceeds from issuance of Series A Preferred Stock | 9,020,000 | - | ||
| Net proceeds from promissory note | 300,000 | - | ||
| Repayment of promissory note | (300,000) | - | ||
| Payment of redemption payable | (5,072,945) | - | ||
| Proceeds from business combination | 726,339 | - | ||
| Purchase of treasury stock | (84,091) | |||
| Net cash provided by financing activities | 13,064,290 | - | ||
| Net Change in Cash | 2,248,144 | (1,429,409) | ||
| Cash at beginning of period | 2,479,146 | 4,088,333 | ||
| Cash at end of period | $4,727,290 | $2,658,924 | ||
| Supplemental Cash Flow Information | ||||
| Cash paid for income tax | $ | - | $ | - |
| Cash paid for interest | $2,663 | $ | - | |
| Supplemental Disclosure of Non-cash Financing Activities | ||||
| Deferred transaction costs included in other payables and accrued liabilities | $ | - | $221,187 | |
| Recognition of related party operating right-of-use asset and lease liability | $ | - | $48,988 | |
| Conversion of Series A prefer stock into common stock | $5,000,000 | $ | - | |
| Conversion of deferred underwriting commission payable into Series A preferred stock | $730,000 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.